Thyroid eye disease (TED) — an autoimmune condition most commonly associated with Graves' disease — causes a distinctive and sometimes devastating constellation of symptoms: protrusion of the eyes, double vision, painful swelling, and in the most severe cases, vision loss. For years, patients in the active inflammatory phase of the disease had one approved pharmacological option. Patients in the chronic, burned-out phase had none.
That has changed with the FDA's June 26, 2026 approval of veligrotug (brand name: Lumvoa), developed by Viridian Therapeutics.
Veligrotug is the first therapy approved with labeling specifically indicating efficacy for both the active phase and the chronic phase of thyroid eye disease — an approval that directly addresses the population of TED patients who had persistent, significant symptoms but had been told they were beyond the window for available treatments.
Why This Matters
TED is a chronically underappreciated condition. Most endocrinologists and primary care physicians are focused on managing the underlying thyroid dysfunction — hyperthyroidism in Graves' disease, or less commonly, hypothyroidism in Hashimoto's thyroiditis — and the eye manifestations can be underestimated until they become severe.
The disease follows a characteristic course: an initial active inflammatory phase in which symptoms rapidly worsen, followed by a plateau, followed by a chronic or "burnt-out" phase in which the inflammatory activity resolves but the resulting structural changes — eye protrusion, double vision, eyelid retraction — may persist indefinitely.
Before veligrotug, the dominant pharmacological treatment for TED was teprotumumab (Tepezza), approved in 2020 and primarily indicated for the active phase of TED. Patients who were in the chronic phase of TED — or who sought care after the active inflammatory window had passed — were typically managed with surgical options or supportive measures alone.
What We Know So Far
Veligrotug is an anti-IGF-1R (insulin-like growth factor-1 receptor) monoclonal antibody — the same general mechanism as teprotumumab — targeting the receptor that drives orbital fibroblast activation and orbital tissue expansion in TED. The IGF-1R pathway is a validated therapeutic target in thyroid eye disease, and both drugs work by blocking this pathway's contribution to the inflammatory and structural changes in the orbit.
The key distinction in veligrotug's approval is its clinical trial program. The FDA approval was supported by the THRIVE trial (active TED) and THRIVE-2 trial (chronic TED) — both phase 3 pivotal trials that enrolled patients across their respective disease phases. Both trials met their primary and all secondary endpoints at week 15:
- Diplopia (double vision) response : Statistically significant improvement versus placebo in both active and chronic TED patients, with complete diplopia resolution also demonstrated in both populations
- Complete proptosis response : Statistically significant improvement in both disease states, with reductions in eye protrusion observed as early as week 3
- Veligrotug is administered as five IV infusions every three weeks over 12 weeks
Important Safety Signals to Know
The FDA label for Lumvoa includes four key warnings and precautions that patients and prescribers should discuss before treatment:
- Hearing impairment — including potentially permanent hearing loss; a baseline hearing assessment is required before treatment begins
- Hyperglycemia — occurring in approximately 12% of patients, including non-diabetics
- Inflammatory bowel disease (IBD) exacerbation — patients with IBD history require specific counseling and monitoring
- Infusion reactions — occurring in approximately 9% of patients
A pregnancy test is also required before starting Lumvoa, which should not be used during pregnancy. Patients of reproductive potential should use effective contraception during treatment and for 6 months after the last dose.
Why Chronic Phase Patients Needed This
A significant portion of TED patients present to physicians after the active inflammatory phase has already passed. This can happen because the active phase was undiagnosed, because patients did not have access to a TED specialist in time, or because the condition was initially mild and only became significantly symptomatic when the chronic structural changes accumulated.
For these patients, the previous standard of care was largely surgical. While orbital decompression surgery can effectively reduce proptosis and relieve optic nerve compression, and eye muscle surgery can address some forms of diplopia, surgical approaches are invasive, require anesthesia, and may need to be staged in sequence. A pharmacological option approved for the chronic phase represents a genuine expansion of the treatment toolkit.
What Doctors and Experts Say
Thyroid eye disease specialists at AJMC have noted that veligrotug's approval is based on the two largest pivotal phase 3 trials completed in TED to date. Endocrinologists who manage the upstream thyroid disease in TED patients will now need to understand veligrotug's indication and be prepared to refer appropriate chronic-phase patients to ophthalmologists or neuro-ophthalmologists who specialize in TED management and can administer the treatment.
Detailed efficacy data have not yet been published in peer-reviewed literature at the time of writing, which limits independent assessment of the magnitude of clinical benefit and long-term durability, particularly in the chronic TED population.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Drug: Veligrotug-vvze (Lumvoa), anti-IGF-1R monoclonal antibody; FDA approved June 26, 2026
- Mechanism: Blocks IGF-1R pathway driving orbital fibroblast activation and tissue expansion
- Approved for: Adult patients with thyroid eye disease, active AND chronic, regardless of disease activity or duration
- Trial evidence: THRIVE (active TED) and THRIVE-2 (chronic TED); all primary and secondary endpoints met at week 15 in both trials
- Key distinction from Tepezza: First drug approved with clinical data in both active and chronic TED phases
- Key safety signals: Hearing impairment (potentially permanent), hyperglycemia (12%), IBD exacerbation risk, infusion reactions (~9%)
- What remains to be seen: Long-term durability data in chronic patients; no head-to-head comparison trial with teprotumumab published
Who Should Consider Asking About Veligrotug?
- Adults with Graves' disease who have developed TED and are experiencing persistent proptosis, double vision, or eyelid changes, whether in the active or chronic disease phase
- Patients who were told they were "past the window" for TED treatment because the active inflammatory phase had passed
- Patients who are not candidates for or are seeking to delay surgical intervention
- Patients who completed a prior treatment cycle with teprotumumab but have persistent residual symptoms
- Note: Patients with IBD, hearing impairment, or diabetes should discuss those conditions specifically with their physician before considering treatment
What You Can Do Now
If you have thyroid eye disease and have been told no medical treatment is available because you are in the chronic phase, ask your ophthalmologist, neuro-ophthalmologist, or endocrinologist about veligrotug.
TED management requires coordination between endocrinology and ophthalmology — if you have Graves' disease and eye symptoms but have not been formally evaluated for TED by an ophthalmologist, request that referral.
Contact the TED Community Organization for patient education resources and physician referral guidance. The manufacturer's patient support program (ViridianCares) can be reached at 866-VCARES1 (866-822-7371) for coverage and access assistance.
Cost and Access: What Patients Should Know
Veligrotug is a specialty biologic administered by infusion. Coverage for TED biologic treatments has historically required prior authorization. Viridian has created the ViridianCares program, providing patient access liaisons, insurance coverage support, and financial assistance for eligible patients.
The Bottom Line
Veligrotug (Lumvoa) is the first treatment approved by the FDA for both the active and chronic phases of thyroid eye disease — directly addressing the gap in pharmacological options for patients with persistent TED symptoms who have moved beyond the active inflammatory window. If you have chronic thyroid eye disease and have been told no medical treatment is available, that conversation is worth revisiting with your physician.
